At Navignostics, we fight cancer by enabling personalized treatments.
We analyze tumor samples and determine the best way to target each cancerous growth, so that clinicians can find the right therapy for each of their patients and researchers can develop new drugs.
Each tumor is unique, which is why each cancer patient needs a unique treatment plan. Navignostics helps clinicians identify the optimal therapy from a single tumor tissue section.
The success of clinical trials depends on selecting the right patient group. Navignostics supports translational research and biomarker identification and helps drug developers recognize the patients that can benefit the most from their novel treatment approach.
We combine highly multiplex protein imaging with advanced data analytics for our spatial single-cell proteomics approach, validated through over a decade of translational and clinical research.
We founded Navignostics in 2022 as a spin-off from the University of Zurich Bodenmiller Lab. Our laboratory and headquarters are located in Horgen, Switzerland, where our growing team of scientists, lab technicians, software developers and business experts work together to solve our partners’ problems.
We wouldn’t be here without the support of our partners and associates.
Let’s combine clinicians’ patient expertise and researchers’ discoveries with Navignostics technologies to build a future where cancer no longer threatens quality of life.
Find out about our latest developments and company updates.
